Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06649110 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

A Phase 1 study of Healthy Volunteers, Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
232
Enrollment target
20
Study locations

NCT06649110 is a Phase 1 study of Healthy Volunteers, Pulmonary Arterial Hypertension that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 232 participants. The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06649110, a Phase 1 study of Healthy Volunteers, Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
232 participants
Enrollment target
20
Study locations

Study Summary

A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)

Interventions

  • DRUG Placebo
  • DRUG LTP

Study Locations (20)

Other

  • Novartis Investigative Site - Prague
  • Novartis Investigative Site - Berlin
  • Novartis Investigative Site - Heidelberg
  • Novartis Investigative Site - Thessaloniki

New South Wales

  • Novartis Investigative Site - Camperdown
  • Novartis Investigative Site - Darlinghurst
  • Novartis Investigative Site - New Lambton Heights

California

  • Stanford Medical Center - Stanford

Colorado

  • Univ Colorado Hospital - Aurora

Kansas

  • U of Kansas Medical Center - Kansas City

Kentucky

  • Norton Infectious Diseases Specialists - Louisville

Massachusetts

  • Tufts Medical Center - Boston

Oregon

  • Summit Health Eastside Clinic - Bend

Trial Details

FieldValue
Enrollment Target 232 participants
Start Date 2024-10-24
Est. Completion 2028-12-31
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

What the Registry Record Tells You About NCT06649110

The ClinicalTrials.gov registry entry for NCT06649110 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers, Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06649110 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, New South Wales, California.

Frequently Asked Questions

What is clinical trial NCT06649110 about?

NCT06649110 is a clinical study titled "A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)". A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)

What is the current status of trial NCT06649110?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 232 participants. The study started on 2024-10-24. Estimated completion is 2028-12-31.

What conditions does trial NCT06649110 study?

This clinical trial studies the following conditions: Healthy Volunteers, Pulmonary Arterial Hypertension.

What interventions are being tested in trial NCT06649110?

The interventions under investigation include: Placebo (DRUG), LTP (DRUG).

Who is sponsoring clinical trial NCT06649110?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06649110 being conducted?

This trial has 20 study locations across California, Colorado, Kansas, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.